Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Dec 15;207(12):2901-2912.
doi: 10.4049/jimmunol.2100424.

Mucosal Immunity in Cystic Fibrosis

Affiliations
Review

Mucosal Immunity in Cystic Fibrosis

Christine M Bojanowski et al. J Immunol. .

Abstract

The highly complex and variable genotype-phenotype relationships observed in cystic fibrosis (CF) have been an area of growing interest since the discovery of the CF transmembrane conductance regulator (CFTR) gene >30 y ago. The consistently observed excessive, yet ineffective, activation of both the innate and adaptive host immune systems and the establishment of chronic infections within the lung, leading to destruction and functional decline, remain the primary causes of morbidity and mortality in CF. The fact that both inflammation and pathogenic bacteria persist despite the introduction of modulator therapies targeting the defective protein, CFTR, highlights that we still have much to discover regarding mucosal immunity determinants in CF. Gene modifier studies have overwhelmingly implicated immune genes in the pulmonary phenotype of the disease. In this context, we aim to review recent advances in our understanding of the innate and adaptive immune systems in CF lung disease.

PubMed Disclaimer

Figures

Figure 1:
Figure 1:
Simplified overview of CFTR in the normal (left) and CF (right) airway and the key aberrancies in innate mucosal immunity namely deyhydrated and thickened airway surface liquid (in part due to increased activity of ENaC), tethered and thickened mucus, decreased pH, impaired mucociliary clearance, hyperinflammation, pathogenic biofilm formation and the establishment of bacterial colonization.
Figure 2:
Figure 2:
Simplified overview of the aberrancies in CF adaptive immunity marked by robust responses that are infective in mediating inflammation and eradicating bacterial pathogens. Insert Panel 1. T helper cells: Th2 and Th17 immune responses predominate in CF. Elevated Th17 cells in CF are associated with worsened lung function with proinflammatory cytokine IL-17A (IL-17) recruiting and activating neutrophils to promote continued inflammation. IFN-γ, a key product of Th1 cells, is an important regulator of neutrophil accumulation and survival. Mucus accumulation and goblet cell hyperplasia are driven by Th2 cells, particularly IL-4 and Il-13. Insert Panel 2. Regulatory T cells: Vitamin D supplementation has been associated with a higher percentage of T reg cells in healthy subjects and in subjects with autoimmune disease. Low levels of T reg cells have been shown in the people with CF and ABPA and is associated with chronic P. aeruginosa infection and lower lung function. Insert Panel 3. B cells: Increased immunoglobulins and elevated circulating immune complexes (CICs) are seen in the CF lung and have been investigated as potential poor prognostic markers in CF given their association with decreased lung function and death particularly in individuals colonized with P. aeruginosa. It is unclear why the immunoglobulin response is ineffective in CF. Defects in somatic hypermutation, impaired antibody transport and entrapment in thickened biofilms and mucous, or increased degradation by proteases have been hypothesized.

References

    1. Rehman A, Baloch NU, and Janahi IA 2015. Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR. N Engl J Med 373: 1783. - PubMed
    1. Middleton PG, Mall MA, Drevinek P, Lands LC, McKone EF, Polineni D, Ramsey BW, Taylor-Cousar JL, Tullis E, Vermeulen F, Marigowda G, McKee CM, Moskowitz SM, Nair N, Savage J, Simard C, Tian S, Waltz D, Xuan F, Rowe SM, Jain R, and Group VXS 2019. Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele. N Engl J Med 381: 1809–1819. - PMC - PubMed
    1. Harrison MJ, Murphy DM, and Plant BJ 2013. Ivacaftor in a G551D homozygote with cystic fibrosis. N Engl J Med 369: 1280–1282. - PubMed
    1. Clancy JP 2018. Rapid therapeutic advances in CFTR modulator science. Pediatr Pulmonol 53: S4–S11. - PMC - PubMed
    1. Lopes-Pacheco M. 2019. CFTR Modulators: The Changing Face of Cystic Fibrosis in the Era of Precision Medicine. Front Pharmacol 10: 1662. - PMC - PubMed

Publication types

Substances